Skip to content
Clinical Trials – home

Centre Hospitalier De Perigueux

Verified siteinfo

France 80 Avenue Georges Pompidou, 24000 Perigueux, France

  • 13 trials recruiting
  • Plasma cell myeloma · Chronic myeloid leukaemia · Follicular lymphoma
  • Adult patients

About Specializations

Centre Hospitalier De Perigueux in Perigueux, France specialises in clinical trials of conditions such as Plasma cell myeloma, Chronic myeloid leukaemia, Follicular lymphoma, Peripheral T-cell lymphoma unspecified, and other specialisations. This site conducts important research.

Main research areas of the site

Virus Diseases and Chronic Hepatitis D

At Centre Hospitalier De Perigueux, research in infectious disease focuses on virus diseases, especially chronic hepatitis D infection. The trial work is aimed at understanding whether a new treatment approach can help slow liver disease progression and reduce liver-related complications over time.

  • Evaluating treatment effectiveness in chronic hepatitis D
  • Tracking long-term liver disease outcomes
  • Assessing prevention of liver-related events

This area reflects a strong interest in improving care for persistent viral infection and its impact on long-term health.

Respiratory Tract Diseases and Community-Acquired Pneumonia

Clinical research also covers respiratory tract diseases, with a focus on community-acquired pneumonia in older adults. The study is designed to compare common antibiotic approaches and determine whether a narrower treatment strategy can perform as well as broader therapy in routine hospital care.

  • Comparing antibiotic strategies for community-acquired pneumonia
  • Studying treatment effectiveness in patients aged 65 years or older
  • Supporting better antimicrobial therapy choices

This work highlights practical research aimed at improving everyday treatment decisions for hospitalized patients with pneumonia.

Bacterial Infections and Mycoses in Hospital Care

The site’s trial portfolio also includes research in bacterial infections, reflecting broader efforts to refine infection management in a hospital setting. These studies look at whether targeted treatment choices can maintain clinical effectiveness while supporting more appropriate use of antibiotics.

  • Evaluating care for bacterial infections
  • Testing the effectiveness of narrower versus broader antimicrobial approaches
  • Improving infection treatment in hospitalized patients

Overall, the research emphasizes better-informed treatment selection for common infectious diseases treated at this hospital.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
80 Avenue Georges Pompidou24000 PerigueuxFrance
Recruiting now
13 trials
Conditions studied
24
Partner status
Verified site

More sites in PerigueuxFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

30 clinical trials

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Intergroupe Francophone Du Myelome

Study Comparing Elranatamab and Lenalidomide with Daratumumab and Lenalidomide for Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Study Comparing Continuous and Fixed Duration Therapy with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Relapsed Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Dexamethasone for Patients with Advanced Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Assistance Publique Hopitaux De Paris

Polycythaemia vera+4

Recruiting

Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Study of tazemetostat combined with lenalidomide and rituximab in adult patients with relapsed or refractory follicular lymphoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Epizyme Inc.

Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Assistance Publique Hopitaux De Paris

Study Comparing Clarithromycin and Azithromycin for Treating Mycobacterium Avium Complex Lung Infections in Adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Pneumonia

Recruiting

Study Comparing Amoxicillin and Amoxicillin/Clavulanic Acid for Treating Community-Acquired Pneumonia in Patients Aged 65 and Older

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Amoxicillin
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Study on the Benefits of Autologous Stem Cell Transplantation for Patients with Peripheral T-cell Lymphoma Using Etoposide and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:LYSARC

Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Universitair Medisch Centrum Utrecht
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Groupe Francophone Des Myelodysplasies
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.